Strategies for management of high risk nondisabling cerebrovascular events

doi:10.3969/j.issn.1006-7795.2017.01.001

Abstract

Abstract: Cerebrovascular events have become the most common cause for death or dependency of Chinese population. Risk assessment model for stroke recurrence was insufficient and effective treatment strategy was lacking. Prof. Yongjun Wang et al carried out a population-based survey and a cohort study with large sample, presented the concept of "high risk patients with acute nondisabling cerebrovascular events", established a risk accessment system for stroke, and found a new dual antiplatelet method which significantly decreased the risk of stroke recurrence by 32% without increasing bleeding events. The new method had been applied in the clinical practice widely, decreased stroke recurrence in 740 000 cases and reduced medical cost by 15 billion yuan.

Key words: cerebrovascular disease, high risk nondisabling, risk, diagnosis, treatment

CLC Number:

R743.3

Wang Yilong, Zhao Xingquan, Wang Yongjun. Strategies for management of high risk nondisabling cerebrovascular events[J]. Journal of Capital Medical University, 2017, 38(1): 1-5.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2017.01.001

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2017/V38/I1/1

References

[1] Johnston S C, Mendis S, Mathers C D, et al. Global variation in stroke burden and mortality:estimates from monitoring, surveillance, and modelling[J]. Lancet Neurol, 2009,8(4):345-354.
[2] Wang Y, Zhao X, Jiang Y, et al. Prevalence, knowledge, and treatment of transient ischemic attacks in china[J]. Neurology,2015, 84(23):2354-2361.
[3] Wang Y, Cui L, Ji X, et al. The China national stroke registry for patients with acute cerebrovascular events:design, rationale, and baseline patient characteristics[J]. Int J Stroke,2011,6(4):355-361.
[4] Li J, Wang Y, Lin J, et al. Soluble CD40L is a useful marker to predict future strokes in patients with minor stroke and transient ischemic attack[J]. Stroke, 2015,46(7):1990-1992.
[5] Lin J, Zheng H, Cucchiara B L, et al. Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke[J]. Neurology,2015, 85(18):1585-1591.
[6] Wang Y, Zhao X, Liu L, et al. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China:The Chinese intracranial atherosclerosis (CICAS) study[J]. Stroke,2014,45(3):663-669.
[7] Meng X, Wang Y, Liu L, et al. Validation of the ABCD²-I score to predict stroke risk after transient ischemic attack[J]. Neurol Res,2011,33(5):482-486.
[8] Furie K L, Kasner S E, Adams R J. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack:a guideline for healthcare professionals from the American heart association/American stroke association[J].Stroke,2011,42(1):227-276.
[9] Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med, 2013,369(1):11-19.
[10] 中华医学会神经病学会, 中华医学会神经病学分会脑血管病学组. 中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2014[J].中华神经科杂志,2015,48(4):258-273.
[11] Poisson S N, Schardt T Q, Dingman A, et al. Etiology and treatment of arterial ischemic stroke in children and young adults[J]. Curr Treat Options Neurol, 2014,16(10):315.
[12] Coutts SB1, Wein T H, Lindsay M P. Canadian stroke best practice recommendations:secondary prevention of stroke guidelines, update 2014[J]. Int J Stroke, 2015, 10(3):282-291.
[13] Wang Y, Pan Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial:One-year outcomes[J]. Circulation, 2015,132(1):40-46.
[14] Wang X, Zhao X, Johnston S C, et al. Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke:CHANCE substudy[J]. Neurology, 2015,85(7):573-579.
[15] Wong K S, Wang Y, Leng X, et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack:an updated systematic review and meta-analysis[J]. Circulation, 2013,128(15):1656-1666.
[16] Wang Y, Zhao X, Lin J, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack[J]. JAMA, 2016,316(1):70-78.
[17] Li J, Wang Y, Wang D, et al. Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke[J]. Neurology,2015,84(13):1330-1336.